drugset / Trial / NCT06222879
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to determine if treatments with the combination of HRS-8080 and SHR-A1811, the combination of HRS-8080 and SHR-A2009, the combination of SHR-A2009 and SHR-1316 are safe, tolerable, and has anti-cancer activity in patients with unresectable or metastatic breast cancer.
Timeline
- Start
- 2024-02-20
- Primary completion
- 2026-10-31
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | HRS-8080 | Unknown | — | — |
| Subject | SHR-A2009 | Other / unclassified | — | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |